Sanofi
Sanofi to buy Dynavax for US$2.2 billion to add shingles vaccine
[PARIS] Sanofi agreed to buy Dynavax Technologies for about US$2.2 billion to expand its vaccines business with a shot for hepatitis B and an experimental shingles inoculation.
Trump pressures 17 pharma CEOs to cut US drug prices
[WASHINGTON] President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash US prescription drug prices to match those paid overseas, the White...
Sanofi to buy Vicebio for up to US$1.6 billion in vaccine push
The French drugmaker will pay US$1.15 billion upfront with a commitment for potential milestones worth as much as US$450 million
Sanofi to buy US biopharma group Blueprint for up to US$9.5 billion
The acquisition represents a strategic step forward in the French drugmaker’s rare and immunology portfolios
Sanofi plans 5 billion-euro buyback, sees higher profit growth
Earnings per share, excluding some items, are likely to increase by a low double-digit percentage at constant currencies in 2025, says the French drugmaker
Sanofi announces biggest China investment deal amid China-EU trade tensions
China is seeking to strengthen economic ties with individual members of the European Union
Sanofi boosts preparedness with S$800 million Singapore plant
Modulus can also be reconfigured within a few days to transform between technological platforms, a process which traditionally takes months or years
Sanofi profit lifted by early vaccine sales, Dupixent growth
Earnings per share excluding some items reached 2.86 euros in Q3
Sanofi enters exclusive talks with CD&R for Opella sale
Sanofi agreed on terms of the deal after providing Paris with guarantees on maintaining jobs and production in France
France seeks job guarantees from Sanofi over Doliprane painkiller production
Doliprane is France’s best-selling drug and news that it could be partially sold to a foreign investor has prompted political concerns
